Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at Weill Cornell Medicine

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 11:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
778
Shown on this page
12
Current sort
Recently updated
Campus scope
Weill Cornell Medicine, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Weill Cornell Medicine, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 541–552 of 778 matching trials with a site at Weill Cornell Medicine, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional Results available

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

NCT04302324
Site status not listed — check the official record
Conditions
Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
Interventions
Daratumumab SC, Clarithromycin, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Recruiting Not applicable Interventional

Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition

NCT06094478
Status at this site: Recruiting
Conditions
Stroke, Acute, Ischemic Stroke, Acute, Hemorrhagic Stroke
Interventions
HI-SPEED Protocol
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
New Haven, Connecticut • Miami, Florida • Atlanta, Georgia + 5 more
Recruiting No phase listed Observational

A Registry for People With T-cell Lymphoma

NCT05978141
Status at this site: Not yet recruiting
Conditions
T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia, Chronic Lymphoproliferative Disorder of NK Cells, Aggressive NK-cell Leukemia, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Adult T-cell Leukemia/Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Enteropathy-associated T-cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Breast Implant-Associated Anaplastic Large Cell Lymphoma
Interventions
Optional Blood Sample and Nail Sample
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
26
States / cities
Duarte, California • San Diego, California • San Francisco, California + 20 more
Active, not recruiting Not applicable Interventional

Pain Reduction Using NEurostimulation Study

NCT05311956
Site status not listed — check the official record
Conditions
End Stage Kidney Disease, Chronic Pain
Interventions
Active tDCS, Sham tDCS
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York
Conditions
Colorectal Cancer Metastatic, Liver Metastases, Colorectal Cancer
Interventions
Botensilimab, Balstilimab, AGEN1423, Radiation
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Tethered Cord, Tethered Cord Syndrome, Occult Spina Bifida, Spina Bifida Occulta
Interventions
Release of filum terminale
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
2 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Recruiting Not applicable Interventional

Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis

NCT03256240
Status at this site: Recruiting
Conditions
Crohn's Disease
Interventions
side-to-side functional end anastomosis, Kono-S analstomosis
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2036
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Oklahoma City, Oklahoma + 3 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

PATHFINDER 2: A Multi-Cancer Early Detection Study

NCT05155605
Site status not listed — check the official record
Conditions
Early Detection of Cancer, Cancer
Interventions
Multi-Cancer Early Detection Test
Device
Lead sponsor
GRAIL, Inc.
Industry
Eligibility
50 Years and older
Enrollment
35,883 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
55
States / cities
Auburn, California • Davis, California • Elk Grove, California + 45 more
Active, not recruiting Phase 3 Interventional

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

NCT03574571
Site status not listed — check the official record
Conditions
Prostate Cancer
Interventions
Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
40
States / cities
Gilbert, Arizona • New Haven, Connecticut • Newark, Delaware + 32 more
Active, not recruiting Phase 2 Interventional

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

NCT05819359
Site status not listed — check the official record
Conditions
Parkinson's Disease
Interventions
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Drug
Lead sponsor
Bial R&D Investments, S.A.
Industry
Eligibility
35 Years to 80 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
43
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 30 more
Active, not recruiting Phase 1Phase 2 Interventional

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

NCT04067336
Site status not listed — check the official record
Conditions
Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia
Interventions
Ziftomenib, Midazolam, Itraconazole
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
20
States / cities
Gilbert, Arizona • Los Angeles, California • Jacksonville, Florida + 16 more
Active, not recruiting Phase 1 Interventional

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia

NCT04150887
Site status not listed — check the official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Cusatuzumab, Azacitidine, Venetoclax
Drug
Lead sponsor
OncoVerity, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
11
States / cities
Duarte, California • Louisville, Kentucky • Detroit, Michigan + 7 more

About this Weill Cornell Medicine institution page

What this page lists
ClinicalTrials.gov records that list Weill Cornell Medicine in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.